Multivariate models to predict clinically important outcomes at prostatectomy for patients with organ-confined disease and needle biopsy Gleason scores of 6 or less

Urologic Oncology: Seminars and Original Investigations

Volumn 21, Issue 6, 2003, Pages 439-446

  Dimarco, David S ^a   Blute, Michael L ^a   Zincke, Horst ^a   Cheville, John C ^a   Riehle, Darren L ^a   Lohse, Christine M ^a   Pankratz, V Shane ^a   Sebo, Thomas J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Clinically confined; Digital image analysis; DNA ploidy; Gleason score; Insignificant tumor; MIB I; Needle biopsy; Prostate carcinoma

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; MULTIVARIATE ANALYSIS; NEEDLE BIOPSY; PERINEURIUM; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; REVIEW; SCORING SYSTEM; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR VOLUME;

EID: 2142754438     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(03)00059-0     Document Type: Article

References (29)

1. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 277:1997;1445-1451
2. Blute M.L., Bergstralh E.J., Iocca A., Scherer B., Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol. 165:2001;119-125
3. Sebo T.J. Digital image analysis. Mayo Clin Proc. 70:1995;81-82
4. Farkas A., Schneider D., Perrotti M., Cummings K.B., Ward W.S. National trends in the epidemiology of prostate cancer, 1973 to 1994 evidence for the effectiveness of prostate-specific antigen screening. Urology. 52:1998;444-448. discussion 448-9
5. Roberts R.O., Bergstralh E.J., Katusic S.K., Lieber M.M., Jacobsen S.J. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol. 161:1999;529-533
6. Catalona W.J., Smith D.S., Ratliff T.L., Basler J.W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 270:1993;948-954
7. Smart C.R. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer. 80:1997;1835-1844
8. Dugan J.A., Bostwick D.G., Myers R.P., Qian J., Bergstralh E.J., Oesterling J.E. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA. 275:1996;288-294
9. Sebo T.J.C.J., Riehle D.L., Lohse C.M., et al. Perineural invasion and MIB-I positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol. 4:2002
10. Sebo T.J., Bock B.J., Cheville J.C., Lohse C., Wollan P., Zincke H. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J of Urol. 163:2000;174-178
11. Sebo T.J., Cheville J.C., Riehle D.L., et al. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen a report of 454 cases. Cancer. 91:2001;2196-2204
12. Epstein J.I., Potter S.R. The pathological interpretation and significance of prostate needle biopsy findings implications and current controversies. J Urol. 166:2001;402-410
13. Freedland S.J., Csathy G.S., Dorey F., Aronson W.J. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason Score. J Urol. 167:2002;516-520
14. Diaz J.I., Mora L.B., Austin P.F., et al. Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation. Urology. 53:1999;931-938
15. Stackhouse G.B., Sesterhenn I.A., Bauer J.J., et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol. 162:1999;2040-2045
16. Bostwick D.G., Wheeler T.M., Blute M., et al. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology. 48:1996;47-57
17. Grossklaus D.J., Coffey C.S., Shappell S.B., Jack G.S., Chang S.S., Cookson M.S. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol. 167:2002;2032-2035. discussion 2036
18. Lewis J.S. Jr, Vollmer R.T., Humphrey P.A. Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population. Am J Clin Pathol. 118:2002;442-450
19. Montgomery B.T., Nativ O., Blute M.L., et al. Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. Arch Surg. 125:1990;327-331
20. Hawkins C.A., Bergstralh E.J., Lieber M.M., Zincke H. Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomy. Urology. 46:1995;356-364
21. Ross J.S., Figge H., Bui H.X., et al. Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. Cancer. 74:1994;2811-2818
22. Brinker D.A., Ross J.S., Tran T.A., Jones D.M., Epstein J.I. Can ploidy of prostate carcinoma diagnosed on needle biopsy predict radical prostatectomy stage and grade? [see comments] J Urol. 162:1999;2036-2039
23. Epstein J.I., Walsh P.C., Carmichael M., Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 271:1994;368-374
24. Shichiri Y., Egawa S., Kamoto T., et al. [A study on parameters to predict tumor volume for stage T1c prostate cancers of Gleason score 6 or less]. Hinyokika Kiyo-Acta Urol Jpn. 46:2000;785-790
25. Eskew L.A., Woodruff R.D., Bare R.L., McCullough D.L. Prostate cancer diagnosed by the 5 region biopsy method is significant disease. J of Urol. 160:1998;794-796
26. Stewart C.S., Leibovich B.C., Weaver A.L., Lieber M.M. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J of Urol. 166:2001;86-91. discussion 91-82.
27. Schmid H.P., McNeal J.E. An abbreviated standard procedure for accurate tumor volume estimation in prostate cancer. Am J of Surg Path. 16:1992;184-191
28. Hollenbeck B.K., Bassily N., Wei J.T., et al. Whole mounted radical prostatectomy specimens do not increase detection of adverse pathological features. J Urol. 164:2000;1583-1586
29. Jack G.S., Cookson M.S., Coffey C.S., et al. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma decreased pathological stage and increased detection of transition zone tumors. J Urol. 168:2002;519-524